Last reviewed · How we verify
Placebo to veliparib
Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death.
Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death. Used for Metastatic breast cancer (in combination with chemotherapy), Ovarian cancer, BRCA-mutated cancers.
At a glance
| Generic name | Placebo to veliparib |
|---|---|
| Sponsor | AbbVie |
| Drug class | PARP inhibitor |
| Target | PARP1/PARP2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PARP enzymes are involved in single-strand DNA break repair. By inhibiting PARP, veliparib prevents cancer cells from repairing DNA damage, leading to accumulation of DNA lesions and cell death. This is particularly effective in tumors with BRCA mutations or homologous recombination deficiency, which rely heavily on PARP-mediated repair pathways.
Approved indications
- Metastatic breast cancer (in combination with chemotherapy)
- Ovarian cancer
- BRCA-mutated cancers
Common side effects
- Nausea
- Fatigue
- Anemia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer (PHASE3)
- Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE3)
- Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer (PHASE1, PHASE2)
- Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer (PHASE2)
- A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (PHASE3)
- Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (PHASE3)
- A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to veliparib CI brief — competitive landscape report
- Placebo to veliparib updates RSS · CI watch RSS
- AbbVie portfolio CI